Critically, the study validated the bridging strategy using OncoHost's PROphet (R) platform--an AI-powered, plasma proteomics-based model designed to predict immunotherapy outcomes in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results